SG10201602147YA - Methods And Compositions For Predicting Response To Eribulin - Google Patents
Methods And Compositions For Predicting Response To EribulinInfo
- Publication number
- SG10201602147YA SG10201602147YA SG10201602147YA SG10201602147YA SG10201602147YA SG 10201602147Y A SG10201602147Y A SG 10201602147YA SG 10201602147Y A SG10201602147Y A SG 10201602147YA SG 10201602147Y A SG10201602147Y A SG 10201602147YA SG 10201602147Y A SG10201602147Y A SG 10201602147YA
- Authority
- SG
- Singapore
- Prior art keywords
- eribulin
- compositions
- methods
- predicting response
- predicting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454426P | 2011-03-18 | 2011-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201602147YA true SG10201602147YA (en) | 2016-05-30 |
Family
ID=45879070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201602147YA SG10201602147YA (en) | 2011-03-18 | 2012-03-16 | Methods And Compositions For Predicting Response To Eribulin |
| SG2013069646A SG193489A1 (en) | 2011-03-18 | 2012-03-16 | Methods and compositions for predicting response to eribulin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013069646A SG193489A1 (en) | 2011-03-18 | 2012-03-16 | Methods and compositions for predicting response to eribulin |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637795B2 (en) |
| EP (1) | EP2686441B1 (en) |
| JP (3) | JP2014509515A (en) |
| CN (1) | CN103562406B (en) |
| CA (1) | CA2828959A1 (en) |
| ES (1) | ES2731653T3 (en) |
| SG (2) | SG10201602147YA (en) |
| WO (1) | WO2012129100A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2928464A1 (en) * | 2012-12-04 | 2015-10-14 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
| US9549922B2 (en) | 2013-06-26 | 2017-01-24 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| KR20170039096A (en) * | 2014-05-28 | 2017-04-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Use of eribulin in the treatment of cancer |
| EP3148336B1 (en) | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| JP6951248B2 (en) | 2015-03-04 | 2021-10-20 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Combination of PD-1 antagonist and eribulin to treat cancer |
| EP4053278A1 (en) | 2015-05-01 | 2022-09-07 | Japan Science and Technology Agency | Anti-tumor agent suppressing or inhibiting zic5 |
| KR102445255B1 (en) | 2016-03-02 | 2022-09-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Eribulin-Based Antibody-Drug Conjugates and Methods of Use |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2020179712A1 (en) * | 2019-03-01 | 2020-09-10 | Eisai R&D Management Co., Ltd. | Methods for predicting tumor response to eribulin |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN113174427B (en) * | 2021-04-29 | 2023-02-28 | 遵义医科大学 | Method for detecting ERGIC3 mRNA based on DNA molecule |
| CN113512733B (en) * | 2021-05-13 | 2022-07-26 | 浙江工业大学 | Method for synthesizing eribulin intermediate through electrochemical NHK reaction |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| DE69233331T3 (en) | 1991-11-22 | 2007-08-30 | Affymetrix, Inc., Santa Clara | Combinatorial Polymersynthesis Strategies |
| US5547835A (en) | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | Nucleic acid analysis techniques |
| ATE291097T1 (en) | 1997-10-31 | 2005-04-15 | Affymetrix Inc A Delaware Corp | EXPRESSION PROFILES IN ADULT AND FETAL ORGANS |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| AU762998B2 (en) | 1998-06-17 | 2003-07-10 | Eisai R&D Management Co., Ltd. | Macrocyclic analogs and methods of their use and preparation |
| US20050208512A1 (en) * | 2003-10-01 | 2005-09-22 | The Ohio State University Research Foundation | Determining the chemosensitivity of cells to cytotoxic agents |
| US20060154312A1 (en) * | 2004-12-09 | 2006-07-13 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using halichondrin B analogs |
| WO2011109637A1 (en) * | 2010-03-03 | 2011-09-09 | Koo Foundation Sun Yat-Sen Cancer Center | Methods for classifying and treating breast cancers |
-
2012
- 2012-03-16 US US14/001,737 patent/US9637795B2/en active Active
- 2012-03-16 CA CA2828959A patent/CA2828959A1/en not_active Abandoned
- 2012-03-16 SG SG10201602147YA patent/SG10201602147YA/en unknown
- 2012-03-16 ES ES12710643T patent/ES2731653T3/en active Active
- 2012-03-16 EP EP12710643.3A patent/EP2686441B1/en active Active
- 2012-03-16 SG SG2013069646A patent/SG193489A1/en unknown
- 2012-03-16 WO PCT/US2012/029479 patent/WO2012129100A1/en active Application Filing
- 2012-03-16 JP JP2013558214A patent/JP2014509515A/en active Pending
- 2012-03-16 CN CN201280013701.8A patent/CN103562406B/en not_active Expired - Fee Related
-
2017
- 2017-03-10 JP JP2017046070A patent/JP6612280B2/en not_active Expired - Fee Related
-
2019
- 2019-04-01 JP JP2019069638A patent/JP2019150027A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019150027A (en) | 2019-09-12 |
| CN103562406B (en) | 2018-03-27 |
| US20140235707A1 (en) | 2014-08-21 |
| JP6612280B2 (en) | 2019-11-27 |
| SG193489A1 (en) | 2013-10-30 |
| CN103562406A (en) | 2014-02-05 |
| JP2017148049A (en) | 2017-08-31 |
| EP2686441B1 (en) | 2019-05-08 |
| US9637795B2 (en) | 2017-05-02 |
| WO2012129100A1 (en) | 2012-09-27 |
| CA2828959A1 (en) | 2012-09-27 |
| JP2014509515A (en) | 2014-04-21 |
| EP2686441A1 (en) | 2014-01-22 |
| ES2731653T3 (en) | 2019-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2742154A4 (en) | Biomarker compositions and methods | |
| EP2721179A4 (en) | Biomarker compositions and methods | |
| SG10201602147YA (en) | Methods And Compositions For Predicting Response To Eribulin | |
| HK1256896A1 (en) | Methods and compositions to enable multiplex cold-pcr | |
| PL2841390T3 (en) | Dimensionally stable geopolymer compositions and method | |
| EP2665726A4 (en) | Compositions and methods for cardiovascular disease | |
| GB201408236D0 (en) | Composition and method | |
| GB201122195D0 (en) | Composition and method | |
| EP2730619A4 (en) | Composition | |
| IL227924A0 (en) | Compositions and methods of use for determination of he4a | |
| GB201411762D0 (en) | Precoating methods and compositions | |
| EP2692796A4 (en) | Composition | |
| ZA201308892B (en) | Compositions and methods | |
| EP2766357A4 (en) | Meso-biliverdin compositions and methods | |
| GB201117037D0 (en) | Composition | |
| GB201108912D0 (en) | Composition | |
| GB201106433D0 (en) | Composition and method | |
| GB201103964D0 (en) | Composition | |
| IL231798A0 (en) | Method and composition | |
| GB201115211D0 (en) | Composition | |
| EP2711011A4 (en) | Panaxadiol-containing composition | |
| GB201116416D0 (en) | Composition | |
| IL230868A0 (en) | Biomarker compositions and methods | |
| GB201116340D0 (en) | Compositions and methods | |
| EP2718455A4 (en) | Organic syringomycin methods and compositions |